6-K
GSK plc (GSK)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2025
Commission File Number 001-15170
GSK plc
(Translation of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc (the 'Company')
Transaction notification
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
|---|---|---|---|---|
| a) | Name | Dr Hal Barron | ||
| b) | Position/status | Non-Executive Director | ||
| c) | Initial<br>notification/amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | American Depositary Shares ('ADSs')<br><br><br><br><br><br>ISIN: US37733W2044 | ||
| b) | Nature<br>of the transaction | Acquisition of notional ADSs within Dr Barron's GSK Executive<br>Supplemental Savings Plan account following the reinvestment of<br>dividends | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| $47.1800 | 2,732.837 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume<br><br><br><br><br><br>Price | ||||
| e) | Date<br>of the transaction | 2025-11-14 | ||
| f) | Place<br>of the transaction | New York Stock Exchange (XNYS) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Dr Hal Barron | ||
| b) | Position/status | Non-Executive Director | ||
| c) | Initial<br>notification/amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | American Depositary Shares ('ADSs')<br><br><br><br><br><br>ISIN: US37733W2044 | ||
| b) | Nature<br>of the transaction | Acquisition of ADSs within Dr Barron's GSK 401(k) plan account<br>following the reinvestment of dividends | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| $47.1800 | 69 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume<br><br><br><br><br><br>Price | ||||
| e) | Date<br>of the transaction | 2025-11-14 | ||
| f) | Place<br>of the transaction | New York Stock Exchange (XNYS) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | James Ford | ||
| b) | Position/status | SVP and Group General Counsel, Legal and Compliance | ||
| c) | Initial<br>notification/amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | American Depositary Shares ('ADSs')<br><br><br><br><br><br>ISIN: US37733W2044 | ||
| b) | Nature<br>of the transaction | Acquisition of notional ADSs within Mr Ford's GSK Executive<br>Supplemental Savings Plan account following the reinvestment of<br>dividends | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| $47.1800 | 50.851 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume<br><br><br><br><br><br>Price | ||||
| e) | Date<br>of the transaction | 2025-11-14 | ||
| f) | Place<br>of the transaction | New York Stock Exchange (XNYS) |
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
| GSK plc | |
|---|---|
| (Registrant) | |
| Date: November<br>18, 2025 | |
| By:/s/ VICTORIA<br>WHYTE<br><br><br>-------------------------- | |
| Victoria Whyte | |
| Authorised<br>Signatory for and on | |
| behalf<br>of GSK plc |